Fujirebio Holdings, Inc. (led by President and Chief Executive Officer Goki Ishikawa) and Sysmex Corporation (headed by President Kaoru Asano) jointly announced today the expansion of their contract development and manufacturing services (CDMO) partnership. This expansion builds upon their prior plans outlined in the Basic Agreement for Business Cooperation in the Immunoassay Field*, signed in October 2023, and now includes collaboration in the field of neural degenerative diseases.

Since 2020, Fujirebio has been actively engaged in developing special reagents for Sysmex's HISCL™ series of automated immunoassay systems. Recognizing the mutual benefits of leveraging their expertise in immunoassays, both companies agreed in October 2023 to deepen their collaboration. Subsequently, discussions were held to explore avenues for reinforcing their partnership.

According to the newly reached agreement, Fujirebio will focus on developing reagents for Sysmex's HISCL™ family of products, specifically for the detection of cerebrospinal fluid (CSF) and blood-based markers related to neurodegenerative diseases, including Alzheimer's disease. This strategic move aims to enhance Sysmex’s detection capabilities in disease-related parameters and accelerate its global presence in the field of immune analysis.

The collaborative efforts between Fujirebio and Sysmex will extend to the swift development and launch of these detection services, reinforcing their commitment to advancing the field of immunoassays and contributing to the global healthcare landscape.

 

Source: businesswire.com

Report Abuse